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Ocular involvement in Anti Phospolipid Syndrome (APS) 
includes a broad spectrum of manifestations from the 
anterior and posterior segment or the presence of 
neuro-ophthalmologic features. A female, 29 years old, 
came to ER handled by ophthalmology department, 
with chief complaint left visual loss suddenly since 4 
hours before admission. Investigations revealed stable 
vital signs, VOD 20/20, VOS 1/300, funduscopy showed 
pale and cherry red spot on left retina, OCT revealed 
hyperreflective of left inner retinal layer, IgG aCL 51.7 U/
mL (50.8 U/mL in OPD 3 months later), and the other 
examinations were within normal limit. Patient was 
diagnosed with Central Retinal Artery Occlusion due to 
Primary Antiphospolipid syndrome. She was performed 
occular massage and anterior chamber paracintesis 
procedure, and given O2 6-8 lpm NRBM, Timolol 0.5% 
eye drop left eye bid, acetazolamide 250 mg bid, Kalium 
Slow Release 1 tab qd, Levofloxacine eye drop 1 drop/
hour post surgery. After the result of IgM aCL available, 
we added warfarin 2 mg qd and aspirin 320 mg qd.  
Patient was discharged 2 days later as visual acuity 
improved with VOD 20/20 and VOS 0.5/60.
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Introduction
Ocular involvement in APS includes a broad 
spectrum of manifestations from the anterior 
and posterior segment or the presence of neuro-
ophthalmologic features.1-4 In brief, conjuctival 
telangiectasia or conjuctival microaneurysms, 
episcleritis, limbal or filamentary keratitis and 
iritis have been described as the APS ocular 
features from the anterior segment,5-9  vitritis, 
retinal detachment, posterior scleritis, branch or 
central retinal vein occlusion, bilateral choroidal 
infarction, cilioretinal artery occlusion, venous 
tortuosity, retinal hemorrhages, cotton-wool spots 
and central serous type chorioretinopathy from the 
posterior segment4,8  and monocular or bilateral 
transient visual loss, transient visual field loss, 
ischemic optic neuropathy and progressive optic 
nerve atrophy as the neuroophthalmologic features 
of APS. It is estimated that the incidence opf APS 
is approximately 5 cases per 100.000 persons per 
year, and 88% of primary APS involved ocular 
involvements.4,5
 However, case report of the ocular manifestations 
as the prevailing sign of APS in patients suffering 
from “unexplained” ocular disease are seldom. 
Herein, we report a sudden left eye visual loss in 
a young female without any other risk factors of 
thrombosis as first manifestation of APS in Malang, 
Indonesia.
Case	Illustration
A female, 29 years old, came to ER handled by 
ophthalmology department, with chief complaint 
left visual loss suddenly since 4 hours before 
admission when she was playing with her nephews 
on the bed. Her left eye suddenly could not see 
anything after she got up from lying on bed. It was 
painless, persistent, non progressive, and redless. 
There were no history of joint pain, skin rash, hair 
loss, fever, eye disease, and episodes of thrombosis 
before. There weren’t also history of trauma, 
hypertension, diabetes, dyslipidemia, malignancy, 
heart disease, blood disorders, nor other systemic 
diseases. However, both parents passed away due 
to heart disease and stroke as complications of 
DM and hypertension. She is an accountant, not 
yet married, and had regular period. She had never 
consumed routine medications and had no drug 
allergy.
 Physical examination revealed blood pressure 
110/70 mmHg, pulse rate 84 bpm, respiratory rate 
12 tpm, axillary temperature 36.7 C, body weight 
56 kg, body height 158 cm, and BMI 22.4 kg/m2, 
VOD 20/20, VOS 1/300, intra occular pressure 
OD was 19.6 mmHg whether OS was 23 mmHg. 
Funduscopy showed pale and cherry red spot on 
left retina. Optical Coherence Tomography (OCT) 
of the left eye revealed hyperreflective of inner 
retinal layer that was a sign of intraretinal oedema 
and ischemia. Anterior segment and the other 
examinations were within normal limit.
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Figure	1. Retina Photo of the Patients Showing CRAO 
(Cherry Red Spot and Pale of the Retina)
Laboratory result showed hemoglobin level 13.60 g/dl, 
leukocyte count 7.240/µL, hematocrite 40.60 %, thrombocyte 
count 281.000/µL, (diff count 0.4/0.3/68.6/27.2/3.5). PPT was 
11.10 second, aPTT was 29.80 (within normal limit), INR 
0.96, random blood glucose 83 mg/dL, Ureum 17.70 mg/dL, 
Creatinine 0.60 mg/dL, CRP 0.10 mg/dL, ESR 19 mm/hour, 
fasting blood glucose 72 mg/dL, 2 hours post prandial glucose 
92 mg/dL, Hba1c 4.60% (average blood glucose 85.3 mg/dL), 
total cholesterol 175 mg/dL, triglyceride 56 mg/dL, HDLc 41 
mg/dL, and LDLc 92 mg/dL, antidsDNA 66.2 IU/mL (N < 
92.6), and ANA test (ELISA)  0.1 (N < 1) units. ECG showed 
sinus rhytm heart rate 80x/m. 
 Patient was consulted to internal medicine department to 
investigate possible cause of blood vessel occlusion in this 
patient. We suggest to checked for aCL for screening of APS. 
The result showed IgG anti cardiolipin antibody 51.7 U/mL. 
We checked again 3 months later in Outpatient Department 
showed 50.8 U/mL.
Figure	2. OCT of Left Eye (Right Picture) that Revealed 
Hyperreflective of Inner Retinal Layer, Compared to Right 
Eye (Left Picture) that Was Within Normal Limit
Patient was diagnosed as Central Retinal Artery Occlusion 
due to Primary Antiphospolipid syndrome. She was performed 
occular massage and anterior chamber parasintesis procedure, 
and given O2 6-8 lpm NRBM, Timolol 0.5% eye drop bid 
on the left eye, acetazolamide 250 mg bid, Kalium Slow 
Release 600mg qd, and Levofloxacine eye drop 1 drop/hour 
post surgery. After the result of IgG aCL available, we added 
warfarin 2 mg qd and aspirin 320 mg qd.  Patient was discharged 
2 days later with improvement of visual acuity (VOD 20/20 
and VOS 0.5/60), and aspirin was stopped afterward in OPD 
with uptitrating warfarin as INR target reached 3.0.
Discussion 
Antiphospolipid syndrome is a hypercoagulable disorder 
manifested by recurrent arterial and venous thromboses 
and adverse outcomes in pregnancy that is associated with 
antiphospolipid (aPL) antibodies.6 The pathophysiology of 
retinal artery occlusion in APS is poorly understood, although 
aPL is implicated in this disorder. aPL affects coagulation and 
thrombosis in different ways: (1) these antibodies may bind 
to platelets, upregulating production of thromboxane A2 and 
expression of glycoprotein 2b-3a, to endothelial cells and 
monocytes which increase production of tissue factors; or to 
endothelial cells resulting in an increase in adhesion molecules; 
which all of them interacts causing thrombosis, (2) the binding 
of aPL also activates complement, which can initiate an 
inflammatory cascade resulting in thrombosis. Complement 
activation has also been linked to fetal loss in APS, (3) 
another journals also mentioned that coagulation may result 
from disruption of proteins that regulate thrombosis, such as 
protein C, by aPL, also antibodies against β-2 glycoprotein 
I (β-2gpI), a naturally occuring anticoagulant, may induce a 
prothrombotic state, (4) cardiovascular risk factors such as 
smoking and estrogen use can help promote thrombosis in 
APS.7 
 This case demonstrated that the ocular features as the first 
presenting sign of APS though rare, should alert the clinicians 
for APS possibility, particularly when conventional risk 
factors have been excluded and the onset of ocular symptoms 
are insidious.5,7,9,11-16 Although the involvement of anterior 
segment is not rare, the manifestations from the posterior 
segment such as vasculitis, vitritis, retinal detachment, 
posterior scleritis and central retinal artery occlusion appear to 
be more prominent among APS patients.4,8 Of these, the most 
common and the most serious is vasculitis, which can result 
in vasoocclusive disseminated retinopathy. In our case, the 
patient came with central retinal artery occlusion without any 
involvement of anterior segment and neuroophthalmology. 
 Acutely, obstruction of the central retinal artery results in 
inner layer edema and pyknosis of the ganglion cell nuclei. 
Ischemic necrosis results, and the retina becomes opacified 
and yellow-white in appearance. The opacity is most dense 
in the posterior pole as a result of the increased thickness 
of the nerve fiber layer and ganglion cells in this region. 
Furthermore, the foveola assumes a cherry-red spot because 
of a combination of 2 factors: (1) the intact retinal pigment 
epithelium and choroid underlying the fovea, and (2) the 
foveolar retina is nourished by the choriocapillaris. The late 
stage shows a homogenous scar replacing the inner layer of 
the retina.4,6
 The updated International Consensus Statement on 
classification criteria for definite APS states that the diagnosis 
of APS should be considered when at least one Clinical Criteria 
( (1) Vascular thrombosis, or (2) Pregnancy morbidity; (a) one 
or more unexplained deaths of a morphologically normal fetus 
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at or beyond the 10th week, (b) one or more pre-term births 
of a morphologically normal neonate before the 34th week 
of gestation because of eclampsia, severe pre-eclampsia, or 
recognized features of placental insufficiency, (c) three or more 
consecutive spontaneous miscarriage before the 10th week of 
gestation with maternal anatomic, hormonal abnormalities, 
and chromosomal causes excluded) and one Laboratory 
Criteria ( (1) Lupus anticoagulant (LA), (2) Anticardiolipin 
(aCL) antibody of IgG and/or IgM isotype, or (3) Anti-β2-
glycoprotein I antibody of IgG and/or IgM isotype, all of those 
three present in plasma or serum on two or more occasions 
at least 12 weeks apart).7,10 Patient in our case presented with 
arterial thrombosis at central retinal artery and elevated titer 
IgM aCL on 2 separated examinations, thus already fulfilled 
diagnostic criteria.
 Prevention of thrombosis is a major goal of therapy in 
patients with aPL antibodies. Therapy is divided into 2 clinical 
settings: primary prophylaxis (aPL carriers without previous 
thrombosis) and secondary prophylaxis (patient with APS 
who have already had a thrombotic events).7-8
 For patients with documented thrombotic events, long 
term intensive anticoagulation is recommended on the basis 
for the type of thrombotic events. Venous events can be treated 
with unfractionated IV heparin followed by warfarin with a 
goal INR of 2.5 (range 2-3). Recurrent venous thrombosis has 
been reported from 3%-24% per year and if it happened, high 
intensity anticoagulant is recommended (INR range 3-4), or 
warfarin (INR 2-3) plus aspirin, or switching to LMWH if 
unstable INR. Evidence to treat arterial event is still lack of 
evidence. Current therapy includes aspirin only (325 mg/day) 
and / or warfarin therapy at moderate / high dose. 7,9
 The mainstay of therapy for CRAO is procedure and 
pharmacologic therapy. Occular massage can dislodge the 
embolus to a point further down the arterial circulation and 
improve retinal perfusion. Anterior chamber parasentesis can 
be performed as a decrease in intraocular pressure is believed 
to allow greater perfusion, pushing emboli further down 
the vascular tree. Intra-arterial fibrinolysis is controversial. 
Limited evidence of improved visual acuity with urokinase 
is available. A few cases of intra-arterial tissue plasminogen 
activator (tPA) administration have been observed to be 
successful.18
 Immediate medical care to lower IOP includes 
acetazolamide 500 mg IV/PO once daily and other topical 
medications. Carbogen therapy (5% CO2, 95% O2) may 
dilates retinal arterioles and increase oxygen delivery to 
ischaemic tissue. Hyperbaric oxygen therapy may beneficial 
if begun within 2-12 hours of onset 18
 Our patient was treated by both rheumatology and 
ophthalmology department. We gave high dose aspirin and 
warfarin with target INR 3.0 at the beginning as secondary 
prophylaxis to prevent another episodes of thrombosis and 
worsening of arterial occlusion. Ophthalmology department 
underwent prompt oxygen administration, occular massage, 
anterior chamber parasentesis, and pharmacological treatment 
to lower intra occular pressure (acetazolamide, timolol) 
for giving greater perfusion in the left eye as visual acuity 
improved. Other therapy modality were not available or still 
debatable about the benefit.
 APS prognosis clearly depends on the severity of the 
disease, the thrombotic events, recurrences and the side effects 
of treatment.3 However, the prognosis of ocular diseases due 
to APS is not well documented, as long-lasting prospective 
studies are missing. Though there is still no definite agreement 
for the duration of anticoagulant treatment, it seems rational 
and prudent to treat these patients lifelong targeting an INR 
between >  3.0, while the role, if any, of corticosteroids is 
unclear. 7,9,17
Conclusion
Antiphospolipid syndrome must be suspected in every patient 
with retinal artery occlusion without any other risk factors. 
Early diagnosis and prompt treatment are very important to 
improve visual acuity and prognosis. Collaboration between 
ophthalmology and rheumatology divisions is needed to 
support proper management for such particular patients.
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